PolyPid (NASDAQ:PYPD) Research Coverage Started at Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of PolyPid (NASDAQ:PYPD) in a report published on Tuesday morning, Marketbeat.com reports. The firm issued a buy rating and a $13.00 price objective on the stock.

A number of other brokerages have also recently commented on PYPD. Craig Hallum started coverage on shares of PolyPid in a research note on Monday, November 4th. They issued a “buy” rating and a $10.00 price objective on the stock. HC Wainwright dropped their price objective on shares of PolyPid from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, December 26th.

PolyPid Stock Up 0.3 %

PYPD opened at $2.99 on Tuesday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.00. The company has a market cap of $14.34 million, a price-to-earnings ratio of -0.38 and a beta of 1.32. PolyPid has a one year low of $2.37 and a one year high of $7.00. The business’s fifty day moving average is $3.10 and its two-hundred day moving average is $3.36.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in PolyPid stock. Stonepine Capital Management LLC acquired a new stake in shares of PolyPid Ltd. (NASDAQ:PYPD) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned 2.89% of PolyPid as of its most recent filing with the Securities & Exchange Commission. 26.47% of the stock is owned by institutional investors and hedge funds.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.